9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: A potential alternative for HIV-infection/AIDS therapy

Journal of Medical Virology

Volumn 64, Issue 3, 2001, Pages 238-244

  Hung, C L ^a   Doniger, J ^a   Palini, A ^a   Snyder, S W ^a   Radonovich, M F ^a   Brady, J N ^a   Pantazis, P ^a   Reza Sadaie, M ^a  

^a NovoMed Pharmaceuticals Inc   (United States)

Author keywords

9 Nitrocamptothecin; Antiviral drugs; HIV AIDS; Human peripheral blood lymphocytes

Indexed keywords

ANTIGEN P24; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; RUBITECAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; TREATMENT PLANNING; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; KINETICS; LYMPHOCYTES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034967284     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.1042     Document Type: Article

References (36)

1. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives
2. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein
3. Telomerase activity, Myc and Bcl-2: Possible indicators of effective therapy of prostate cancer with 9-nitrocamptotheicn
4. Metabolism of 4′-azidothymidine: A compound with potent and selective activity against the human immunodeficiency virus
5. The effect of camptothecin on topoisomerase I catalysis
6. A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency
7. Molecular biology of the human immunodeficiency virus type 1
8. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors
9. Human immunodeficiency viruses regulated by alternative trans-activators: Genetic evidence for a novel non-transcriptional function of Tat in virion infectivity
10. Pharmacokinetics of CPT-11 in rhesus monkeys
11. Rapid and sensitive detection of cell-associated HIV-1 in latently infected cell lines and in patient cells using sodium-n-butyrate induction and RT-PCR
12. The other camptothecins: Recent advances with camptothecin analogues other than irinotecan and topotecan
13. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication
14. DNA topoisomerases: Biochemistry and molecular biology
15. Programmed death of T cells in HIV-1 infection
16. Molecular targets for AIDS therapy
17. 9-Nitrocamptothecin inhibits tumor-necrosis factor-mediated activation of the human immunodeficiency virus type 1 (HIV-1) and enhances apoptosis in a latently infected T-cell clone
18. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer drugs
19. Camptothecins: A review of their development and schedules of administration
20. Biochemical basis for the interactions of type I and type II topoisomerases with DNA
21. Preclinical studies of water-insoluble camptothecin congeners: Cytotoxicity, development of resistance, and combination treatments
22. The water-insoluble camptothecin analogues: Promising drugs for the effective treatment of haematological malignancies
23. Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro
24. The camptothecins: From discovery to the patient
25. Water-insoluble camptothecin analogs as potential antiviral drugs
26. Conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human blood cells in vitro
27. Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts
28. DNA topoisomerases I and II cleavage sites in DNA promoter region
29. 9-Nitrocamptothecin (9NC) selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9NC-resistant U937 monocytoid cells
30. Acquisition of cellular resistance to 9-nitrocamptothecin correlates with suppression of transcription factor NF-kB and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells
31. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer
32. Genetic regulation of human immunodeficiency virus
33. Animal models for studying the action of topoisomerase I targeted drugs
34. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor
35. Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I